The End of Alzheimer?s: The First Program to Prevent and Reverse Cognitive Decline

Dale Bredesen

ISBN 10: 0735216207 / ISBN 13: 9780735216204

Edité par Penguin Putnam Inc, 2017

A propos de cet article

2017. 1st Edition. Hardcover. . . . . .

N° de réf. du vendeur V9780735216204

Détails bibliographiques

• Titre: The End of Alzheimer?s: The First Program to Prevent and Reverse Cognitive Decline
• Éditeur: Penguin Putnam Inc
• Date de parution: 2017
• Langue: anglais
• ISBN à 10 chiffres: 0735216207
• ISBN à 13 chiffres: 9780735216204
• Reliure: Couverture rigide
• Édition: Edition originale
• État de l'article: New

A propos de ce titre

Synopsis

The instant New York Times and Wall Street Journal bestseller

A groundbreaking plan to prevent and reverse Alzheimer’s Disease that fundamentally changes how we understand cognitive decline.
 
Everyone knows someone who has survived cancer, but until now no one knows anyone who has survived Alzheimer's Disease. 
 
In this paradigm shifting book, Dale Bredesen, MD, offers real hope to anyone looking to prevent and even reverse Alzheimer's Disease and cognitive decline.  Revealing that AD is not one condition, as it is currently treated, but three, The End of Alzheimer’s outlines 36 metabolic factors (micronutrients, hormone levels, sleep) that can trigger "downsizing" in the brain. The protocol shows us how to rebalance these factors using lifestyle modifications like taking B12, eliminating gluten, or improving oral hygiene.
 
The results are impressive. Of the first ten patients on the protocol, nine displayed significant improvement with 3-6 months; since then the protocol has yielded similar results with hundreds more. Now, The End of Alzheimer’s brings new hope to a broad audience of patients, caregivers, physicians, and treatment centers with a fascinating look inside the science and a complete step-by-step plan that fundamentally changes how we treat and even think about AD.

À propos de l?auteur

Dale Bredesen, M.D., is internationally recognized as an expert in the mechanisms of neurodegenerative diseases such as Alzheimer’s disease. He graduated from Caltech, then earned his M.D. from Duke University Medical Center in Durham, North Carolina. He served as chief resident in neurology at the University of California, San Francisco (UCSF) before joining Nobel laureate Stanley Prusiner’s laboratory at UCSF as an NIH postdoctoral fellow. He held faculty positions at UCSF, UCLA, and the University of California, San Diego. Dr. Bredesen directed the Program on Aging at the Burnham Institute before coming to the Buck Institute in 1998 as its founding president and CEO. He is the chief medical officer of MPI Cognition.